FDA clears Fluidda's digital lung imaging platform for respiratory disease monitoring

Dandelion
Using CT scans, 3D image processing and airflow simulations, Fluidda hopes to provide more accurate and clinically relevant information on function among different lung regions. (Pixabay)

The FDA cleared a new digital imaging platform designed to give doctors a clear peek into a person’s lung function—allowing them to diagnose different respiratory diseases by visualizing factors such as the flow of blood through the organ with each breath. 

Fluidda’s Broncholab software derives several biomarkers following a low-dose CT scan procedure, including maps of ventilation and any trapped air pockets as well as airway and nodule volume in different lung regions.

The platform can also predict how drug particles are deposited throughout the lung when inhaled, with those patterns providing information to help optimize treatment.  

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

According to Fluidda, when a person is sick with a respiratory disease, the lungs tend to compensate for underperforming areas of the organ to help maintain airflow. This can obscure the full picture of a person’s lung health when using tests that gauge how much air a person can exhale, like spirometry.

Blood vessels in the different lobes
of the lungs, based on Fluidda's
imaging technology (Fluidda)

RELATED: New coronavirus maps offer insights for detection and treatment  

Using high-resolution CT scans—plus its digital image processing, 3D modeling and computational airflow simulations—the Belgium-based company’s BronchoLab system aims to provide more accurate and clinically relevant information on perfusion among different lung regions.

“We are living in a time where respiratory viruses cause significant disruption to daily life with high associated cost,” Fluidda CEO Jan De Backer said in a statement. “We are striving to better understand respiratory illnesses with our novel technology to be more prepared for the next viral outbreak and to deal with the increased number of patients with lung diseases worldwide."

In February, Fluidda published a paper in the European Respiratory Journal showing its system could identify patients with progressive idiopathic pulmonary fibrosis (IPF) versus those with stable disease. The company said that airway volume data could be used to help select patients who will see their IPF progress for enrollment in clinical trials.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.